Skip to main content

Windtree Therapeutics Inc

WINT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946486

No open-market purchases or sales by Windtree Therapeutics Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Windtree Therapeutics Inc changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of WINT: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders25127+3
Shares1.60M4.09K1.73M+135.4K (+8.5%)
Value$664.4K$2.00K$518.7K−$143.7K (−21.7%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Windtree Therapeutics Inc at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to WINT in Q3 2022
InstitutionSharesValue% of portfolio
PVG Asset Management Corp187,060$56.1K0.22%
Two Sigma Securities, LLC45,999$14.0K0.00%
Susquehanna International Group, LLP16,075$5.00K0.00%
Cetera Investment Advisers15,255$5.00K0.00%
Game Plan Financial Advisors, LLC10,000$3.00K0.00%
Addison Advisors LLC166$00.00%

Sold out (3)

Institutions that held Windtree Therapeutics Inc at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of WINT in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Two Sigma Advisers, LP84,700$35.0K
Captrust Financial Advisors1,500$1.00K
Blue Bell Private Wealth Management, LLC5$0

Not filed for Q3 2022 yet (1)

Institutions that held Windtree Therapeutics Inc at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding WINT in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Urban Wealth Management, LLC4,087$2.00K